EUCTR2008-004124-23-GB进行中（未招募）不适用
A 12 week, multicentre, open label study to evaluate the efficacy, tolerability and safety of a Fesoterodine flexible dose regimen in patients with overactive bladder
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 326
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must meet all of the following inclusion criteria to be eligible for enrolment into the trial:
- •1. Male or female outpatients =18 years old.
- •2. Overactive bladder symptoms (subject-reported) for =3 months prior to Screening/Visit 1.
- •3. Mean urinary frequency of ?=8 micturitions per 24 hours as verified by the screening bladder diary prior to Baseline/Visit 2.
- •4. Mean number of Urgency episodes =3 per 24 hours as verified by the screening bladder diary prior to Baseline/Visit 2 (Urgency episodes are defined as those with Urinary Sensation Scale rating =3).
- •5. Rate their bladder as causing (Some) Moderate Problems”, Severe Problems” or Many Severe Problems” on the Patient Perception of Bladder Condition (PPBC) Questionnaire at Visit 2.
- •6. Able and willing to complete the micturition bladder diaries and all trial related
- •questionnaires, comply with scheduled clinic visits and clinical trial procedures.
- •7. Capability of understanding and having signed the informed consent form after full
- •discussion of the treatment and its risk and benefits.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Any condition that would contraindicate the usage of fesoterodine including, but not limited to: hypersensitivity to the active substance (fesoterodine fumarate) or any of the excipients, or to peanut or soya; urinary retention; gastric retention; uncontrolled narrow angle glaucoma; myasthenia gravis; moderate or severe hepatic impairment (Child Pugh C); severe renal impairment; severe ulcerative colitis, and toxic megacolon.
- •2.Neurologic conditions, such as stroke, multiple sclerosis, spinal cord injury, or Parkinson’s disease.
- •3.Stage 3 or greater pelvic organ prolapse, defined as tissue protruding to or beyond the introitus in lithotomy position at rest (without increase in intra abdominal pressure).
- •4.History of lower urinary tract surgery (eg, incontinence surgery or surgery to reduce prostate size; or transurethral resection of the prostate (TURP) or bladder (TURBT) with the exception of any minor surgery (eg, cystoscopic procedures)) within the past 6 months.
- •5.A known history of interstitial cystitis or a significant pain component associated with OAB symptoms, uninvestigated haematuria, urogenital cancer, interstitial or external radiation to the pelvis or external genitalia, or bladder outlet obstruction due to vesical neck contracture, clinical suspicion of prostate carcinoma, mullerian duct cysts, urethral obstruction due to stricture/valves/sclerosis or urethral tumour, radiation cystitis, genito-urinary tuberculosis, bladder calculi, or detrusor-sphincter dyssynergia.
- •6.Active bladder stones. Subjects with a previous history of bladder stones may be included.
- •7.Previous history of acute urinary retention requiring catheterization, clinically relevant bladder outlet obstruction or severe voiding difficulties in the judgment of the investigator, prior to Visit 2.
- •8.Use of an indwelling catheter or an intermittent self-catheterisation programme.
- •9.Symptoms of incontinence being predominately stress urinary incontinence as determined by the investigator.
- •10.Urinary tract infection (UTI) as shown by the results of the urinalysis at Screening or recurrent urinary tract infection (RUTIs) defined as treatment for UTI ?3 times in the last year.
- •11.Use of any electrostimulation, bladder training, or pelvic floor exercises (with certified incontinence practitioners) within 4 weeks prior to Visit 1.
- •12.Treatment with antimuscarinic OAB medication within 3 weeks prior to Visit 2, including any preparation containing:
- •Darifenacin, oxybutynin, propiverine, tolterodine, fesoterodine, solifenacin and trospium.
- •13.Initiation of treatment during the 16 week trial period with:
- •Any drug treatment for overactive bladder.
- •Any drugs with significant anticholinergic, antispasmodic, parasympathetic, or cholinergic agonistic effects.
- •14.Intermittent or unstable use of diuretics or alpha blockers, or tricyclic antidepressants, oestrogen therapy and any 5AR inhibitors or initiation of such treatment(s) within 2 weeks prior to Visit 2.
- •15.Treatment with moderate or potent CYP3A4 inhibitors, such as grapefruit juice, macrolide antibiotics (erythromycin, clarithromycin), immunosuppressants (cyclosporine), azole antifungal agents (ie, ketoconazole, itraconazole), protease inhibitors within 3 weeks prior to Visit 2
- •16.Administration of medications capable of inducing hepatic enzyme metabolism or transport (eg, barbiturates, rifampicin, carbamazepine, phenytoin, primidone, or St. John’s Wort).
- •17.Participated in any clinical trial or received any inv
研究者
相似试验
进行中（未招募）
1 期
This study is looking to see if fesoterodine has an effect on the sexual function of women with overactive bladder problems.sexual function of women with overactive bladder syndromeMedDRA version: 18.1Level: LLTClassification code 10040482Term: Sexual function abnormalSystem Organ Class: 100000004872MedDRA version: 18.0Level: LLTClassification code 10059617Term: Overactive bladderSystem Organ Class: 100000004857EUCTR2010-023851-27-GBKings College Hospital NHS Foundation Trust132
进行中（未招募）
不适用
A 12-week, open label, multicentre study assessing the efficcay and of Donepezil in patients discontinuing treatment with Memantine monotherapyAlzheimer's diseaseEUCTR2004-004918-17-CZPfizer Inc100
进行中（未招募）
不适用
A 12-week, open label, multicentre study assessing the efficcay and of Donepezil in patients discontinuing treatment with Memantine monotherapyMedDRA version: 7Level: VTcClassification code 10012271Alzheimer's diseaseEUCTR2004-004918-17-DEPfizer Limited100
进行中（未招募）
不适用
A 12-week, open label, multicentre study assessing the efficcay and of Donepezil in patients discontinuing treatment with Memantine monotherapyMedDRA version: 7Level: VTcClassification code 10012271Alzheimer's diseaseEUCTR2004-004918-17-FIPfizer Inc.100
进行中（未招募）
1 期
A 12-week, open label, multicentre study assessing the efficcay and of Donepezil in patients discontinuing treatment with Memantine monotherapyEstudio abierto y multicéntrico de 12 semanas de duración para valorar la eficacia y seguridad de Donepezilo en pacientes tras suspender el tratamiento con Memantina en monoterapiaAlzheimer's diseaseEUCTR2004-004918-17-ESPfizer, S.A.100